Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FATIMS – Fampyra and T cell Immunity in Multiple Sclerosis
2013-001409-10Phase 4Terminated
- Sponsor
- University Hospital Odense
- Start
- Aug 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of dalfampridine in multiple sclerosis (MS) (2 arms), sponsored by University Hospital Odense. Primary endpoints: Frequency of T cell subsets, Frequency of memory T cell subtypes and 2 more. Started Aug 2013; status: terminated.
02
Drugs
dalfampridine
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on 2013-001409-10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-001409-10.